Business
European Patent Granted for Lead ARIUS Antibody
European Patent Granted for Lead ARIUS Antibody.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTSX: ARI\n\n\nTORONTO, Jan. 17 /CNW/ - ARIUS Research Inc. (TSX: ARI) announced today\nthat it has received notice from the European Patent Office that Patent\nEP1613656B1 has been granted under the Patent Cooperation Treaty (PCT). This\npatent addresses one of the anti-cancer antibodies in ARIUS's lead program for\nbreast and prostate cancers targeting the CD59 antigen. CD59 is important\nbecause it can be used by cancer cells to evade the body's immune system and\nis associated with worse patient outcomes.\n\n\nPreviously, ARIUS had received a Notice of Allowance for the\ncorresponding patent from the United States Patent and Trademark Office. PCT\npatents are important additions to the ARIUS Intellectual Property portfolio\nthat expand protection outside the United States and are essential to\ndetermining worldwide value for business development and licensing activities.\nThis patent protects the antibody molecule and ways of identifying patients\nwho carry the antibody target and could potentially benefit from therapy\ninvolving such a molecule.\n\n\nARIUS has over 80 patents pending that will continue to enhance the value\nof the company.\n\n\n\"This is the first European patent for our CD59 program\" said Dr. David\nYoung, President and CEO of ARIUS. \"Our worldwide Intellectual property\nstrategy has been very successful and we are pleased to announce such an\nimportant patent for one of our novel lead programs.\"\n\n\nARIUS Research Inc. is a biotechnology company dedicated to the discovery\nand development of novel anticancer monoclonal antibodies (MAbs) focused on\ndestroying cancer cells. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs\ntargeting a variety of cancer indications. This antibody generation engine has\nenabled ARIUS to assemble a growing pipeline, which is used for commercial\ncollaborations and in-house development. ARIUS has ongoing partnerships with\nkey biotechnology and drug development companies. The company is listed on the\nTSX under the symbol \"ARI\".\n\n\nForward-Looking Statement\n\n\nCertain statements in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\n...